IN THE CLAIMS:

1. (Currently Amended) A pharmaceutical composition comprising:

a biocompatible carrier for injection or infusion, and an isolated and purified N-terminal fragment of agglutinin like sequences (ALS1) cell surface adhesion protein (SEQ ID No. 8 ~~7~~) obtained from *Candida albicans*, wherein the composition produces an effective immune response in a patient.

2. (Cancelled)

3. (Previously Presented) The composition of Claim 1, wherein the protein contains an adhesion binding site of *Candida albicans*.

4 - 8. (Cancelled)

9. (Currently Amended) The composition of claim 1 wherein the N terminal fragment of the ALS1 protein is encoded by nucleotides 52 to 1296 of the nucleotide sequence of SEQ ID No. 7.

10. (Currently Amended) A pharmaceutical composition consisting essentially of:

a biocompatible carrier for injection or infusion, and an isolated and purified N-terminal fragment of agglutinin like sequences (ALS1) cell surface adhesion protein (SEQ ID NO. 8) obtained from *Candida albicans*, wherein the composition produces an effective immune response in a patient.

11. (Previously Presented) The composition of Claim 10 ~~1~~, wherein the protein contains an adhesion binding site of *Candida albicans*.

12. (Currently Amended) The composition of claim 10 ~~1~~ wherein the N terminal fragment of the ALS1 protein is encoded by nucleotides 52 to 1296 of the nucleotide sequence SEQ ID NO~~e~~. 7.